At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 447 enrolled
Drug / intervention
Brinzolamide/brimonidine ophthalmic suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide/Brimonidine Ophthalmic Suspension 1% to Simbrinza® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes
In Brief
A Phase 3 clinical trial evaluating Brinzolamide/brimonidine ophthalmic suspension and Simbrinza 0.2%/1% Ophthalmic Suspension for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 447 participants across 1 site.
Detailed Summary
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartMay 2021
First PostedJun 2021
Primary CompletionMar 2022
Study CompletionJun 2022
TodayJul 2026
First PostedJun 29, 2021
Enrollment StartMay 28, 2021
Primary CompletionMar 11, 2022
Study CompletionJun 21, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.0 years ago
Interventions
Brinzolamide/brimonidine ophthalmic suspensiondrug
Test product
Simbrinza 0.2%/1% Ophthalmic Suspensiondrug
Reference product